Connect with us

Hi, what are you looking for?

Oracle of  Omaha Says – Investing and Stock NewsOracle of  Omaha Says – Investing and Stock News

Editor's Pick

Curaleaf stock price analysis: sell in May and go away

Curaleaf (CURA) stock price has been in a strong bearish trend in the past few months as the cannabis sector’s hype evaporates. The shares plunged to a low of $3.30 on Thursday, meaning that they have fallen by over 85% from the all-time high in 2020. In the same period, the Global X Cannabis ETF (POTX) stock has crashed by over 90%.

Perils of investing in hype

In March, I wrote an article where I warned against the risks of investing in trending areas. At the time, I warned that most hyped artificial intelligence stocks like and Guardforce AI would crash. I also cited the hot AI cryptocurrencies like SingularityNET (AGIX) and

The same tragedy has happened in the cannabis industry. A few years ago, cannabis stocks like Tilray Brands and Aurora Cannabis were the hottest in the financial market. Today, most of them have seen their shares plunge by over 80%.

Curaleaf stock price has plunged hard in the past few months as the industry has lost hype. Earlier this month, the company said that its revenue jumped by 14% to $352 million in the last quarter. Its gross and EBITDA margins jumped to 47% and 21%, respectively. Further, its operating cash flow came in at $46 million even as the company spent $18 million in its international business.

Curaleaf has also made several strategic initiatives to improve profitability. For example, it has exited some of its key loss-making markets and is now focusing on Florida, Germany, and the UK. In a statement, Boris Jordan, the chairman said:

“Curaleaf will be on offense while others play defense. Make no mistake, we enter 2023 with a cleaner inventory position, ample cash on hand, and we will be investing in our business.” 

Despite these initiatives, the company expects to have low to mid-single-digit growth this year. This is a relatively slow growth for a company in a high-growth industry.

Curaleaf stock price forecast

CURA chart by TradingView

Turning to the weekly chart, we see that the CURA share price has been in a strong bearish trend in the past few months. The shares have moved below the important support level at $3.70, the lowest level on March 2020. It has also retested that support point, which is a sign of a bearish continuation.

Therefore, Curaleaf share price will likely continue falling as sellers target the next key support point at $2.50. At this stage, I don’t support catching this falling knife.

The post Curaleaf stock price analysis: sell in May and go away appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Editor's Pick

    Everynet, one of the world’s largest network operators for national LoRaWAN® networks, announces it is working with Amazon Web Services (AWS) to offer long-range...


    As more candidates throw their hats into the 2024 Presidential ring, I’d like to offer a proposal that should have immediate bipartisan support: stop...

    Editor's Pick

    The Internet of Things (IoT) is changing the way we interact with technology, and it has the potential to revolutionize the way we manage...

    Editor's Pick

    Semtech Corporation and esteemed engineering design services firm, Connected Development, today announced the launch of the new XCVR Development Board and Reference Design integrating...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023